Aquestive Therapeutics, Inc. (AQST)
4.80
+0.14
(+3.00%)
USD |
NASDAQ |
Aug 24, 16:00
4.71
-0.09
(-1.88%)
After-Hours: 20:00
Aquestive Therapeutics Profit Margin (Quarterly) : -165.5% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -165.5% |
| March 31, 2026 | -55.77% |
| December 31, 2025 | -244.8% |
| September 30, 2025 | -120.6% |
| June 30, 2025 | -135.4% |
| March 31, 2025 | -263.0% |
| December 31, 2024 | -143.7% |
| September 30, 2024 | -84.99% |
| June 30, 2024 | -13.66% |
| March 31, 2024 | -106.4% |
| December 31, 2023 | -61.42% |
| September 30, 2023 | -15.65% |
| June 30, 2023 | -43.74% |
| March 31, 2023 | 72.46% |
| December 31, 2022 | -115.6% |
| September 30, 2022 | -109.4% |
| June 30, 2022 | -122.9% |
| March 31, 2022 | -107.7% |
| December 31, 2021 | -261.3% |
| Date | Value |
|---|---|
| September 30, 2021 | -109.5% |
| June 30, 2021 | -80.59% |
| March 31, 2021 | -131.9% |
| December 31, 2020 | -284.9% |
| September 30, 2020 | -200.4% |
| June 30, 2020 | -10.77% |
| March 31, 2020 | -188.6% |
| December 31, 2019 | -76.96% |
| September 30, 2019 | -148.3% |
| June 30, 2019 | -184.0% |
| March 31, 2019 | -116.5% |
| December 31, 2018 | -82.88% |
| September 30, 2018 | -113.3% |
| June 30, 2018 | -262.0% |
| March 31, 2018 | 17.51% |
| December 31, 2017 | -82.33% |
| September 30, 2017 | 31.13% |
| June 30, 2017 | -52.93% |
| March 31, 2017 | -8.86% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| LENZ Therapeutics, Inc. | -581.8% |
| ANI Pharmaceuticals, Inc. | 8.65% |
| Corcept Therapeutics, Inc. | 16.45% |
| Veru, Inc. | -- |
| Johnson & Johnson | 21.86% |
Profit Margin (Quarterly) Related Metrics
| Return on Assets | -56.47% |
| Return on Invested Capital | -83.54% |
| Gross Profit Margin (Quarterly) | 70.93% |
| Operating Margin (Quarterly) | -59.50% |
| Return on Net Operating Assets | -315.6% |